How has been the historical performance of Indo US Bio-Tech?

Answer:The historical performance of Indo US Bio-Tech shows a steady growth in net sales and profitability over the past three years.

Breakdown:
Indo US Bio-Tech's net sales increased from 39.76 Cr in March 2020 to 50.06 Cr in March 2022, reflecting a consistent upward trend. The total operating income followed the same pattern, rising from 39.76 Cr in March 2020 to 50.06 Cr in March 2022. However, raw material costs surged significantly from 3.59 Cr in March 2020 to 45.20 Cr in March 2022, indicating increased production expenses. Despite this, the operating profit (PBDIT) improved from 3.99 Cr in March 2020 to 6.95 Cr in March 2022, showcasing enhanced operational efficiency. Profit before tax also rose from 2.86 Cr in March 2020 to 5.31 Cr in March 2022, while profit after tax increased from 2.53 Cr to 5.06 Cr in the same period. The company's total assets grew from 34.70 Cr in March 2020 to 55.20 Cr in March 2022, alongside total liabilities which increased from 34.70 Cr to 55.20 Cr. The cash flow from operating activities turned positive in March 2022 at 2.00 Cr, compared to zero in the previous years, indicating improved cash generation capabilities. Overall, Indo US Bio-Tech has demonstrated a positive trajectory in its financial performance over the last three years.